Developer docs
API playgroundTry for free, no card

Search company profiles

宜明昂科生物医药技术(上海)有限公司

Full company profile

uuid0045rmx

Namestring
宜明昂科生物医药技术(上海)有限公司
Legal namestring
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage biopharmaceutical company founded in June 2015 by Dr. Tian Wenzhi and headquartered in Shanghai, China, with a Hong Kong Stock Exchange listing (01541.HK) since September 2023. The company develops immuno-oncology biologics that systematically engage both the innate and adaptive immune systems, with a pipeline of 10+ in-house originated assets targeting hematological malignancies, solid tumors, and autoimmune diseases. Core technology includes the proprietary mAb-Trap bispecific antibody platform (yielding CD47×CD20, CD47×HER2, VEGF×PD-L1, and CD47×PD-L1 candidates), the SIRPα-Fc fusion protein design (timdarpacept/IMM01, the first such molecule to enter clinical development in China), and a recombinant human hyaluronidase (rHuPH20) platform enabling subcutaneous delivery of macromolecular drugs.

Lead assets timdarpacept (IMM01) and amulirafusp alfa (IMM0306) are in Phase III for chronic myelomonocytic leukemia (CMML) and relapsed/refractory follicular lymphoma respectively, while palverafusp alfa (IMM2510) is in Phase III for squamous NSCLC with global rights (ex-Greater China) licensed to Instil Bio/Axion Bio in a deal valued at over US$2 billion. The pipeline also includes tazlestobart (IMM27M, CTLA-4), IMM2902 (CD47×HER2, FDA Fast Track), IMM2520, IMM47, IMM40H, and IMM72 (pulmonary arterial hypertension).

The company is pre-revenue with no commercial product sales. Revenue mechanics consist of upfront payments, development/registration/commercial milestones, and single-digit to low double-digit royalties under licensing agreements, plus future direct sales upon regulatory approval. Manufacturing is conducted through wholly-owned subsidiary ImmuneOnco BioPharm (Shanghai) Co., Ltd., established in September 2021 in Zhangjiang Science City, while global commercialization outside Greater China is structured through licensing partners (primarily Instil Bio) and an in-house US-based business development function led by the Chief Business Officer.

Short descriptiontext

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, HKEX-listed immuno-oncology company developing bispecific antibodies and fusion proteins that engage both innate and adaptive immune systems to treat hematological malignancies, solid tumors, and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology biologics, bispecific antibody therapeutics, clinical-stage biopharmaceutical, recombinant fusion proteins, cancer immunotherapy drug development
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Immuno-Oncology Biologics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

ImmuneOnco receives upfront payments, development/registration/commercial milestone payments, and single-digit to low double-digit sales royalties under licensing agreements. Example: Instil Bio/Axion Bio deal worth over $2 billion for IMM2510 and IMM27M outside Greater China.

cn.immuneonco.com
2Pharmaceutical Product Sales (Future)
TypeHardware Sales
Description

Pre-revenue clinical-stage company. Revenue expected from global commercialization of its pipeline of immuno-oncology biologics upon regulatory approvals.

cn.immuneonco.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ImmuneOnco is a clinical-stage biopharmaceutical company developing immuno-oncology biologics, including bispecific antibodies built on its proprietary mAb-Trap platform, SIRPα-Fc fusion proteins, and recombinant protein therapeutics. Its pipeline of 10+ in-house originated drug candidates targets both innate and adaptive immune pathways for hematologic malignancies (e.g., CMML, follicular lymphoma), solid tumors (e.g., NSCLC, TNBC, HER2-positive cancers), and autoimmune diseases (e.g., SLE, IgG4-RD). The company currently monetizes selected assets (IMM2510 and IMM27M) through an ex-Greater China licensing deal with Instil Bio/Axion Bio valued at over US$2 billion and is building toward direct commercialization upon regulatory approvals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase III CMML trial (IMM01): 173 patients enrolled, 2 months ahead of original timeline
+4 more records
Product overview1 text field

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, science-driven biotechnology company dedicated to developing immuno-oncology therapies. The company has built a diversified pipeline of 10+ in-house developed assets including drug candidates and proprietary technology platforms. Key products include: Timdarpacept (IMM01), a first-in-China SIRPα-Fc fusion protein targeting CD47 in Phase III for CMML; Amulirafusp Alfa (IMM0306), a CD47×CD20 bispecific antibody in Phase III for follicular lymphoma and expanding into autoimmune diseases; Palverafusp Alfa (IMM2510), a VEGF×PD-L1 bispecific antibody in Phase III for NSCLC with global rights licensed to Instil Bio; Tazlestobart (IMM27M), an ADCC-enhanced CTLA-4 antibody in Phase II for breast cancer; and IMM2902, a CD47×HER2 bispecific in Phase I. The company operates proprietary mAb-Trap and hyaluronidase technology platforms enabling bispecific antibody development and subcutaneous drug delivery respectively.

Product and service5 records
1Timdarpacept (IMM01)
CategoryDrug Candidate (Oncology — Hematological Malignancies)
Description

First SIRPα-Fc fusion protein targeting CD47 developed in China. Designed with IgG1 Fc to fully activate macrophages via dual mechanism: blocking the 'don't eat me' signal through CD47/SIRPα disruption and delivering an 'eat me' signal via Fcγ receptor engagement on macrophages. Engineered to avoid binding human red blood cells (avoiding the antigen sink effect), with approximately half the molecular weight of regular IgG providing better tissue permeability. In Phase III for CMML and classic Hodgkin lymphoma.

2Amulirafusp Alfa (IMM0306)
CategoryDrug Candidate (Oncology — B-cell Lymphomas / Autoimmune)
Description

CD47×CD20 bispecific antibody developed on the mAb-Trap platform. Does not bind human erythrocytes and has higher affinity for CD20 than rituximab, with stronger ADCC/ADCP activity. In Phase III for relapsed/refractory follicular lymphoma, Phase II/III for IgG4-RD, and Phase II for SLE, lupus nephritis, and membranous nephropathy.

3Palverafusp Alfa (IMM2510)
CategoryDrug Candidate (Oncology — Solid Tumors)
Description

VEGF×PD-L1 bispecific antibody with mAb-Trap structure. Inhibits angiogenesis and sensitizes tumor cells to immune response while activating T cells, NK cells, and macrophages via PD-1/PD-L1 blockade and ADCC/ADCP induction. Differentiated by VEGF trap binding multiple VEGF receptor ligands beyond VEGF-A. In Phase III for squamous NSCLC and Phase II for first-line NSCLC in combination with chemotherapy. Licensed to Instil Bio outside Greater China.

4Tazlestobart (IMM27M)
CategoryDrug Candidate (Oncology — Solid Tumors)
Description

Next-generation CTLA-4 antibody with enhanced ADCC activity. Genetically engineered to induce potent immune responses targeting CTLA-4 overexpressed immune-suppressive Treg cells and promote Treg depletion from the tumor microenvironment. In Phase II for ER+ breast cancer and Phase Ib/II with osimertinib for EGFR-mutated NSCLC. Licensed to Instil Bio outside Greater China.

5IMM2902
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-16
Description

Global registrational strategy for IMM2510/SYN-2510 (PD-L1xVEGF bispecific antibody) in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Joint global Phase 3 trials planned. ImmuneOnco leads China development; Instil leads US development.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

License and collaboration agreement worth over $2 billion for IMM2510 and IMM27M. ImmuneOnco retains commercial rights in Greater China and receives upfront payment, development milestones, and single-digit to low double-digit sales royalties outside Greater China. Received aggregate of $50 million upfront and milestone payments as of August 2025, with over $2 billion in potential remaining milestone and royalty payments.

3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (stock code: SHA: 688336)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-24
Description

Clinical trial collaboration for IMM01 (CD47 SIRPα-Fc fusion protein) combined with Inetetamab (Cipterbin) in HER2-positive solid tumors. Collaboration mainly conducted by Sunshine Guojian.

cn.immuneonco.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based PD-1-focused biotech (toripalimab) actively expanding into bispecific antibodies and combination oncology regimens; comparable in therapeutic area (immuno-oncology), China commercialization focus, and HKEX-listed status.

2I-Mab Biopharma
TypeDirect peer
Description

Clinical-stage China-US biotech focused on immuno-oncology biologics including bispecific antibodies; directly comparable as a clinical-stage Chinese biotech developing oncology biologics targeting similar mechanisms and indications.

TypeDirect peer
Description

Clinical-stage Chinese biotech developing bispecific antibodies and immunology therapeutics with similar pipeline depth and HKEX-listed profile; overlapping CD20/CD47/oncology therapeutic focus makes it a comparable peer.

TypeDirect peer
Description

China-based immuno-oncology biotech developing PD-1, PD-L1, and bispecific antibodies for hematologic and solid tumors; comparable in clinical-stage profile, oncology focus, and Greater China commercialization strategy.

TypeDirect peer
Description

China-based biopharmaceutical company developing monoclonal and bispecific antibodies in oncology (including PD-1, PD-L1, CD47-related targets); directly comparable to ImmuneOnco in pipeline modality, China commercial market focus, and HKEX-listed status.

TypeDirect peer
Description

Chinese clinical-stage biotech developing bispecific antibodies including ivonescimab (PD-1×VEGF), the most direct competitor to ImmuneOnco's IMM2510 in NSCLC; shares the same bispecific antibody modality, oncology focus, and China-listed biotech profile.

TypeBroad incumbent
Description

Global commercial-stage oncology biotech with broad pipeline including hematology assets (e.g., BRUKINSA); comparable as a major China-headquartered immuno-oncology company with global commercial reach competing for similar patient populations.

8Genor Biopharma
TypeDirect peer
Description

Hong Kong-listed Chinese biotech developing monoclonal and bispecific antibodies for oncology and autoimmune diseases; overlapping therapeutic area and pipeline modality (immuno-oncology biologics) and clinical-stage profile.

TypeOthers
Description

ImmuneOnco's primary global licensing partner (NASDAQ: TIL) holding ex-Greater China rights to IMM2510 and IMM27M; while not a direct product competitor, Instil Bio is integral to ImmuneOnco's commercial value capture and US clinical execution.

TypeDirect peer
Description

Developer of magrolimab (CD47 monoclonal antibody), the most advanced Western CD47 program and the most direct mechanistic competitor to ImmuneOnco's IMM01 SIRPα-Fc fusion protein in hematologic malignancies.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

宜明昂科生物医药技术(上海)有限公司

Immuno-Oncology Biologicscn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, HKEX-listed immuno-oncology company developing bispecific antibodies and fusion proteins that engage both innate and adaptive immune systems to treat hematological malignancies, solid tumors, and autoimmune diseases.

What 宜明昂科生物医药技术(上海)有限公司 does

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage biopharmaceutical company founded in June 2015 by Dr. Tian Wenzhi and headquartered in Shanghai, China, with a Hong Kong Stock Exchange listing (01541.HK) since September 2023. The company develops immuno-oncology biologics that systematically engage both the innate and adaptive immune systems, with a pipeline of 10+ in-house originated assets targeting hematological malignancies, solid tumors, and autoimmune diseases. Core technology includes the proprietary mAb-Trap bispecific antibody platform (yielding CD47×CD20, CD47×HER2, VEGF×PD-L1, and CD47×PD-L1 candidates), the SIRPα-Fc fusion protein design (timdarpacept/IMM01, the first such molecule to enter clinical development in China), and a recombinant human hyaluronidase (rHuPH20) platform enabling subcutaneous delivery of macromolecular drugs.

Lead assets timdarpacept (IMM01) and amulirafusp alfa (IMM0306) are in Phase III for chronic myelomonocytic leukemia (CMML) and relapsed/refractory follicular lymphoma respectively, while palverafusp alfa (IMM2510) is in Phase III for squamous NSCLC with global rights (ex-Greater China) licensed to Instil Bio/Axion Bio in a deal valued at over US$2 billion. The pipeline also includes tazlestobart (IMM27M, CTLA-4), IMM2902 (CD47×HER2, FDA Fast Track), IMM2520, IMM47, IMM40H, and IMM72 (pulmonary arterial hypertension).

The company is pre-revenue with no commercial product sales. Revenue mechanics consist of upfront payments, development/registration/commercial milestones, and single-digit to low double-digit royalties under licensing agreements, plus future direct sales upon regulatory approval. Manufacturing is conducted through wholly-owned subsidiary ImmuneOnco BioPharm (Shanghai) Co., Ltd., established in September 2021 in Zhangjiang Science City, while global commercialization outside Greater China is structured through licensing partners (primarily Instil Bio) and an in-house US-based business development function led by the Chief Business Officer.

宜明昂科生物医药技术(上海)有限公司 firmographics

Firmographics
Name
宜明昂科生物医药技术(上海)有限公司
Legal name
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
Website
https://cn.immuneonco.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, HKEX-listed immuno-oncology company developing bispecific antibodies and fusion proteins that engage both innate and adaptive immune systems to treat hematological malignancies, solid tumors, and autoimmune diseases.
Ownership category
akta.pro rank

宜明昂科生物医药技术(上海)有限公司 industry classification

Industry
Product category
Immuno-Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-oncology biologics
  • Bispecific antibody therapeutics
  • Clinical-stage biopharmaceutical
  • Recombinant fusion proteins
  • Cancer immunotherapy drug development

Where 宜明昂科生物医药技术(上海)有限公司 is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

宜明昂科生物医药技术(上海)有限公司 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Licensing and Milestone Payments: ImmuneOnco receives upfront payments, development/registration/commercial milestone payments, and single-digit to low double-digit sales royalties under licensing agreements. Example: Instil Bio/Axion Bio deal worth over $2 billion for IMM2510 and IMM27M outside Greater China.
  2. Pharmaceutical Product Sales (Future): Pre-revenue clinical-stage company. Revenue expected from global commercialization of its pipeline of immuno-oncology biologics upon regulatory approvals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

宜明昂科生物医药技术(上海)有限公司 product offering

Product offering

Core offering

ImmuneOnco is a clinical-stage biopharmaceutical company developing immuno-oncology biologics, including bispecific antibodies built on its proprietary mAb-Trap platform, SIRPα-Fc fusion proteins, and recombinant protein therapeutics. Its pipeline of 10+ in-house originated drug candidates targets both innate and adaptive immune pathways for hematologic malignancies (e.g., CMML, follicular lymphoma), solid tumors (e.g., NSCLC, TNBC, HER2-positive cancers), and autoimmune diseases (e.g., SLE, IgG4-RD). The company currently monetizes selected assets (IMM2510 and IMM27M) through an ex-Greater China licensing deal with Instil Bio/Axion Bio valued at over US$2 billion and is building toward direct commercialization upon regulatory approvals.

Product overview

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, science-driven biotechnology company dedicated to developing immuno-oncology therapies. The company has built a diversified pipeline of 10+ in-house developed assets including drug candidates and proprietary technology platforms. Key products include: Timdarpacept (IMM01), a first-in-China SIRPα-Fc fusion protein targeting CD47 in Phase III for CMML; Amulirafusp Alfa (IMM0306), a CD47×CD20 bispecific antibody in Phase III for follicular lymphoma and expanding into autoimmune diseases; Palverafusp Alfa (IMM2510), a VEGF×PD-L1 bispecific antibody in Phase III for NSCLC with global rights licensed to Instil Bio; Tazlestobart (IMM27M), an ADCC-enhanced CTLA-4 antibody in Phase II for breast cancer; and IMM2902, a CD47×HER2 bispecific in Phase I. The company operates proprietary mAb-Trap and hyaluronidase technology platforms enabling bispecific antibody development and subcutaneous drug delivery respectively.

Differentiator

Problem solved

Functional benefit

Products and services

  • Timdarpacept (IMM01) First SIRPα-Fc fusion protein targeting CD47 developed in China. Designed with IgG1 Fc to fully activate macrophages via dual mechanism: blocking the 'don't eat me' signal through CD47/SIRPα disruption and delivering an 'eat me' signal via Fcγ receptor engagement on macrophages. Engineered to avoid binding human red blood cells (avoiding the antigen sink effect), with approximately half the molecular weight of regular IgG providing better tissue permeability. In Phase III for CMML and classic Hodgkin lymphoma.
  • Amulirafusp Alfa (IMM0306) CD47×CD20 bispecific antibody developed on the mAb-Trap platform. Does not bind human erythrocytes and has higher affinity for CD20 than rituximab, with stronger ADCC/ADCP activity. In Phase III for relapsed/refractory follicular lymphoma, Phase II/III for IgG4-RD, and Phase II for SLE, lupus nephritis, and membranous nephropathy.
  • Palverafusp Alfa (IMM2510) VEGF×PD-L1 bispecific antibody with mAb-Trap structure. Inhibits angiogenesis and sensitizes tumor cells to immune response while activating T cells, NK cells, and macrophages via PD-1/PD-L1 blockade and ADCC/ADCP induction. Differentiated by VEGF trap binding multiple VEGF receptor ligands beyond VEGF-A. In Phase III for squamous NSCLC and Phase II for first-line NSCLC in combination with chemotherapy. Licensed to Instil Bio outside Greater China.
  • Tazlestobart (IMM27M) Next-generation CTLA-4 antibody with enhanced ADCC activity. Genetically engineered to induce potent immune responses targeting CTLA-4 overexpressed immune-suppressive Treg cells and promote Treg depletion from the tumor microenvironment. In Phase II for ER+ breast cancer and Phase Ib/II with osimertinib for EGFR-mutated NSCLC. Licensed to Instil Bio outside Greater China.
  • IMM2902

Quantifiable outcome

  • Phase III CMML trial (IMM01): 173 patients enrolled, 2 months ahead of original timeline
  • +4 more outcomes

Companies that use 宜明昂科生物医药技术(上海)有限公司

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

宜明昂科生物医药技术(上海)有限公司 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

宜明昂科生物医药技术(上海)有限公司 partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Instil Bio / Axion BioflagshipStrategic or Co-development Partner · 16 September 2024Global registrational strategy for IMM2510/SYN-2510 (PD-L1xVEGF bispecific antibody) in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Joint global Phase 3 trials planned. ImmuneOnco leads China development; Instil leads US development.
  • Instil Bio / Axion Bio (formerly SynBioTx)flagshipStrategic or Co-development Partner · 1 August 2024License and collaboration agreement worth over $2 billion for IMM2510 and IMM27M. ImmuneOnco retains commercial rights in Greater China and receives upfront payment, development milestones, and single-digit to low double-digit sales royalties outside Greater China. Received aggregate of $50 million upfront and milestone payments as of August 2025, with over $2 billion in potential remaining milestone and royalty payments.
  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (stock code: SHA: 688336)coreStrategic or Co-development Partner · 24 August 2021Clinical trial collaboration for IMM01 (CD47 SIRPα-Fc fusion protein) combined with Inetetamab (Cipterbin) in HER2-positive solid tumors. Collaboration mainly conducted by Sunshine Guojian.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

宜明昂科生物医药技术(上海)有限公司 competitors and assessment

Company assessment

Direct peers

  • Junshi Biosciences: China-based PD-1-focused biotech (toripalimab) actively expanding into bispecific antibodies and combination oncology regimens; comparable in therapeutic area (immuno-oncology), China commercialization focus, and HKEX-listed status.
  • I-Mab Biopharma: Clinical-stage China-US biotech focused on immuno-oncology biologics including bispecific antibodies; directly comparable as a clinical-stage Chinese biotech developing oncology biologics targeting similar mechanisms and indications.
  • Keymed Biosciences: Clinical-stage Chinese biotech developing bispecific antibodies and immunology therapeutics with similar pipeline depth and HKEX-listed profile; overlapping CD20/CD47/oncology therapeutic focus makes it a comparable peer.
  • CStone Pharmaceuticals: China-based immuno-oncology biotech developing PD-1, PD-L1, and bispecific antibodies for hematologic and solid tumors; comparable in clinical-stage profile, oncology focus, and Greater China commercialization strategy.
  • Innovent Biologics: China-based biopharmaceutical company developing monoclonal and bispecific antibodies in oncology (including PD-1, PD-L1, CD47-related targets); directly comparable to ImmuneOnco in pipeline modality, China commercial market focus, and HKEX-listed status.
  • Akeso, Inc. Chinese clinical-stage biotech developing bispecific antibodies including ivonescimab (PD-1×VEGF), the most direct competitor to ImmuneOnco's IMM2510 in NSCLC; shares the same bispecific antibody modality, oncology focus, and China-listed biotech profile.
  • Genor Biopharma: Hong Kong-listed Chinese biotech developing monoclonal and bispecific antibodies for oncology and autoimmune diseases; overlapping therapeutic area and pipeline modality (immuno-oncology biologics) and clinical-stage profile.
  • Trillium Therapeutics (Gilead): Developer of magrolimab (CD47 monoclonal antibody), the most advanced Western CD47 program and the most direct mechanistic competitor to ImmuneOnco's IMM01 SIRPα-Fc fusion protein in hematologic malignancies.

Broad incumbents

  • BeiGene, Ltd. Global commercial-stage oncology biotech with broad pipeline including hematology assets (e.g., BRUKINSA); comparable as a major China-headquartered immuno-oncology company with global commercial reach competing for similar patient populations.

Others

  • Instil Bio, Inc. ImmuneOnco's primary global licensing partner (NASDAQ: TIL) holding ex-Greater China rights to IMM2510 and IMM27M; while not a direct product competitor, Instil Bio is integral to ImmuneOnco's commercial value capture and US clinical execution.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks2 records

Key highlights7 records

Customer concentration

宜明昂科生物医药技术(上海)有限公司 social profiles

Digital presence

宜明昂科生物医药技术(上海)有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

宜明昂科生物医药技术(上海)有限公司 leadership team

Management profile

Number of profiles

Profiles9 records

宜明昂科生物医药技术(上海)有限公司 subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

宜明昂科生物医药技术(上海)有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

宜明昂科生物医药技术(上海)有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 宜明昂科生物医药技术(上海)有限公司

What does 宜明昂科生物医药技术(上海)有限公司 do?

ImmuneOnco is a clinical-stage biopharmaceutical company developing immuno-oncology biologics, including bispecific antibodies built on its proprietary mAb-Trap platform, SIRPα-Fc fusion proteins, and recombinant protein therapeutics. Its pipeline of 10+ in-house originated drug candidates targets both innate and adaptive immune pathways for hematologic malignancies (e.g., CMML, follicular lymphoma), solid tumors (e.g., NSCLC, TNBC, HER2-positive cancers), and autoimmune diseases (e.g., SLE, IgG4-RD). The company currently monetizes selected assets (IMM2510 and IMM27M) through an ex-Greater China licensing deal with Instil Bio/Axion Bio valued at over US$2 billion and is building toward direct commercialization upon regulatory approvals.

Is 宜明昂科生物医药技术(上海)有限公司 a public or private company?

宜明昂科生物医药技术(上海)有限公司 is a public company. It is classified as public and is currently operating.

When was 宜明昂科生物医药技术(上海)有限公司 founded?

宜明昂科生物医药技术(上海)有限公司 was founded in 2015. It employs 11 to 50 people.

Where is 宜明昂科生物医药技术(上海)有限公司 based?

宜明昂科生物医药技术(上海)有限公司 is headquartered in Shanghai, China, in the Asia region.

How does 宜明昂科生物医药技术(上海)有限公司 make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are pharmaceutical Product Sales (Future).

Who are 宜明昂科生物医药技术(上海)有限公司's main competitors?

Direct peers on record are Junshi Biosciences, I-Mab Biopharma, Keymed Biosciences, CStone Pharmaceuticals, Innovent Biologics, Akeso, Inc., Genor Biopharma and Trillium Therapeutics (Gilead). BeiGene, Ltd. is listed as a broad incumbent. Instil Bio, Inc. is listed as an others.

Does 宜明昂科生物医药技术(上海)有限公司 have an API?

No public API is recorded for 宜明昂科生物医药技术(上海)有限公司.

What industry is 宜明昂科生物医药技术(上海)有限公司 in?

宜明昂科生物医药技术(上海)有限公司's product category is Immuno-Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAD, Fusion Proteins & Fc-Engineered Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales